Snake Venom Peptides Could Be the Next Generation of Antibiotics
Snake venoms contain antimicrobial peptides that kill drug-resistant bacteria through multiple mechanisms, and new delivery technologies may finally make them safe enough for therapeutic use.
Quick Facts
What This Study Found
Snake venoms contain a diverse arsenal of bioactive peptides and proteins that kill bacteria through multiple mechanisms: punching holes in cell membranes, enzymatically degrading microbial structures, generating oxidative stress, breaking up biofilms, and modulating the immune system. These compounds show broad-spectrum activity against drug-resistant bacteria in lab settings.
The review also highlights a newer discovery — snake venom-derived extracellular vesicles (SVEVs) — tiny membrane-bound packages that protect venom compounds from degradation and improve their delivery to target sites. Advanced delivery strategies including PEGylation, liposomes, hydrogels, microneedle patches, and nanoparticles are being developed to reduce the toxicity of these venom compounds while preserving their antimicrobial potency.
Key Numbers
Not applicable (narrative review covering multiple venom compound classes and delivery strategies)
How They Did This
This is a narrative review published in Toxins that synthesizes research on snake venom-derived antimicrobial compounds, their mechanisms of action, delivery technologies (PEGylation, liposomes, hydrogels, microneedle patches, nanoparticles), and the emerging role of snake venom extracellular vesicles in therapeutic delivery.
Why This Research Matters
With antibiotic resistance projected to cause millions of deaths annually by 2050, the search for alternative antimicrobials has become urgent. Snake venom represents a largely untapped natural pharmacy — millions of years of evolution have produced peptides specifically designed to kill microorganisms. The key challenge is separating the antimicrobial activity from the toxic effects, and modern delivery technologies are making this increasingly feasible.
The Bigger Picture
Snake venom research is part of a broader movement to mine nature's chemistry for new medicines. Venoms from snakes, spiders, scorpions, and marine creatures have already yielded FDA-approved drugs (like ziconotide from cone snails and captopril inspired by pit viper venom). Applying modern drug delivery and peptide engineering technologies to venom-derived antimicrobials could produce a new class of antibiotics that bacteria haven't had the chance to evolve resistance against.
What This Study Doesn't Tell Us
As the review itself acknowledges, most antimicrobial activity data for snake venom compounds comes from in vitro (lab dish) studies with limited translational relevance. Long-term safety in animals or humans is largely unexplored. Venom compounds carry inherent toxicity risks that delivery technologies must overcome. Manufacturing these complex biological molecules at pharmaceutical scale remains a major hurdle. The field is in its early stages with no snake venom-derived antimicrobials currently in clinical trials.
Questions This Raises
- ?Which specific snake venom peptides are closest to being tested in animal models of drug-resistant infection?
- ?Can snake venom extracellular vesicles be produced at scale for therapeutic delivery?
- ?How do snake venom antimicrobial peptides compare in potency and safety to synthetic antimicrobial peptides already in clinical trials?
Trust & Context
- Key Stat:
- Multi-mechanism killing Snake venom compounds attack bacteria through at least five different mechanisms simultaneously, making resistance development extremely difficult
- Evidence Grade:
- This is a review article covering a field where the vast majority of evidence is from in vitro laboratory studies. No snake venom-derived antimicrobials have reached clinical testing. The 'Preliminary' grade reflects the early-stage nature of this research despite the breadth of the review.
- Study Age:
- Published in 2025, this is a very current review that captures the latest developments including snake venom extracellular vesicles and modern delivery technologies — representing the cutting edge of this research area.
- Original Title:
- Snake Venom Compounds: A New Frontier in the Battle Against Antibiotic-Resistant Infections.
- Published In:
- Toxins, 17(5) (2025)
- Authors:
- Muttiah, Barathan, Hanafiah, Alfizah
- Database ID:
- RPEP-12689
Evidence Hierarchy
Frequently Asked Questions
How can something as dangerous as snake venom be turned into a medicine?
Snake venom is a complex mixture — some components are toxic to humans while others specifically target bacteria. Scientists can isolate the antimicrobial peptides and modify them to reduce toxicity. Modern delivery technologies like nanoparticles and PEGylation can further protect patients by delivering the active compounds only where they're needed, while preventing them from causing widespread harm.
Why would bacteria have trouble developing resistance to venom peptides?
Most antibiotics attack bacteria through a single mechanism — like blocking cell wall synthesis. Bacteria can develop resistance by altering that one target. Snake venom peptides attack through multiple mechanisms simultaneously: disrupting membranes, generating oxidative stress, breaking up biofilms, and enzymatically degrading microbial structures. Developing resistance to all of these at once is exponentially harder for bacteria.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12689APA
Muttiah, Barathan; Hanafiah, Alfizah. (2025). Snake Venom Compounds: A New Frontier in the Battle Against Antibiotic-Resistant Infections.. Toxins, 17(5). https://doi.org/10.3390/toxins17050221
MLA
Muttiah, Barathan, et al. "Snake Venom Compounds: A New Frontier in the Battle Against Antibiotic-Resistant Infections.." Toxins, 2025. https://doi.org/10.3390/toxins17050221
RethinkPeptides
RethinkPeptides Research Database. "Snake Venom Compounds: A New Frontier in the Battle Against ..." RPEP-12689. Retrieved from https://rethinkpeptides.com/research/muttiah-2025-snake-venom-compounds-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.